Actively Recruiting
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Led by Center for International Blood and Marrow Transplant Research · Updated on 2023-08-30
544
Participants Needed
1
Research Sites
557 weeks
Total Duration
On this page
Sponsors
C
Center for International Blood and Marrow Transplant Research
Lead Sponsor
N
National Marrow Donor Program
Collaborating Sponsor
AI-Summary
What this Trial Is About
Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients with MM. However, the significant morbidity and mortality of this procedure historically limited its application in older patients. Thus, although potentially curative, standard risk MM patients have excellent prognoses in the era of novel therapies which reduces the overall benefit of alloHCT. However, because the outcomes for high-risk MM remain poor despite the best available standard therapies (overall survival of 24-36 months), initial data suggest that alloHCT should be explored in this subset.
CONDITIONS
Official Title
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Medicare beneficiary
- Stage II or III multiple myeloma and/or primary plasma cell leukemia
- Eligible to receive an allogeneic hematopoietic cell transplant from any suitable donor including umbilical cord blood
- Will receive allogeneic hematopoietic cell transplant at a US transplant center
- Agree to submit comprehensive clinical data on pre- and post-transplant status and outcomes to the CIBMTR
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Center for International Blood and Marrow Transplant Research
Minneapolis, Minnesota, United States, 55401
Actively Recruiting
Research Team
M
Mona Patel
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here